MENU

Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices

Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health care spending is on people with diabetes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story